CalciMedica misses second quarter 2026 EPS estimates as FDA aligns on pancreatitis trial design

CalciMedica reported a second quarter 2026 net loss of $0.45 per share, missing consensus estimates by $0.12. Despite the wider loss, the company achieved a critical regulatory milestone with FDA alignment on its Phase 2b trial design for Auxora in acute pancreatitis and bolstered its balance sheet through a $49 million private placement.

Key Highlights

• FDA alignment on the Phase 2b acute pancreatitis trial design confirms the primary endpoint will measure whether Auxora reduces new-onset severe respiratory failure.
• Cash and cash equivalents reached $18.6 million at quarter-end, with a projected runway into the second half of 2027 following the June 2026 private placement financing.
• Research and development expenses declined 49% year-over-year to $2.1 million, driven by reduced clinical trial activities and a transition toward the next phases of development.